Millán-Guerrero RO, Isais-Millán S

Language: Spanish
References: 26
Page: 508-512
PDF size: 147.80 Kb.

ABSTRACT

Cannabis (marijuana) is one of the most consumed psychoactive substances in the world. The term marijuana is of Mexican origin. The primary cannabinoids that have been studied to date include cannabidiol and delta-9-tetrahydrocannabinol, which is responsible for most cannabis physical and psychotropic effects. Recently, the endocannabinoid system was discovered, which is made up of receptors, ligands and enzymes that are widely expressed in the brain and its periphery, where they act to maintain balance in several homeostatic processes. Exogenous cannabinoids or naturally-occurring phytocannabinoids interact with the endocannabinoid system. Marijuana must be processed in a laboratory to extract tetrahydrocannabinol and leave cannabidiol, which is the product that can be marketed. Some studies suggest cannabidiol has great potential for therapeutic use as an agent with antiepileptic, analgesic, anxiolytic, antipsychotic, anti-inflammatory and neuroprotective properties; however, the findings on cannabinoids efficacy and cannabis-based medications tolerability-safety for some conditions are inconsistent. More scientific evidence is required in order to generate recommendations on the use of medicinal cannabis.

REFERENCES

1. Kuddus M, Ginawi IAM, Al-Hazimi A. Cannabis sativa: an ancient wild edible plant of India. Emir J Food Agric. 2013;25:736-745.

2. Elsohly MA, Slade D. Chemical constituents of marijuana: The complex mixture of natural cannabinoids. Life Sci. 2005;78:539-548.

3. Schultes RE, Klein WM, Plowman T, Lockwood TE. Cannabis: an example of taxonomic neglect. Bot Mus Lealf Harv Univ.1974;23:337-367.

4. Williamson EM, Evans FJ. Cannabinoids in clinical practice. Drugs. 2000;60:1303-1314.

5. Small E. Evolution and classification of cannabis sativa (marijuana, hemp) in relation to human utilization. Bot Rev. 2015;81:189-294.

6. Lannotti FA, Di Marzo V, Petrosino S. Endocannabinoids and endocannabinoid- related mediators: targets, metabolism and role in neurological disorders. Prog Lipid Res. 2016;62:107-128.

7. Russo E, Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses. 2006;66:234-246.

8. Russo EB. Cannabidiol claims and misconceptions. Trends Pharmacol Sci. 2017;38:198-201.

9. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346 561-564.

10. Di Marzo V, Piscitelli F. The endocannabinoid system and its modulation by phytocannabinoids. Neurotherapeutics. 2015;12:692-698.

11. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258:1946-1949.

12. Morena M, Patel S, Bains JS, Hill MN. Neurobiological interactions between stress and the endocannabinoid system. Neuropsychopharmacology. 2016;41:80-102.

13. Russo EB, Burnett A, Hall B, Parker KK. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res. 2005;30:1037-1043.

14. Benito C, Tolon RM, Pazos MR, Núñez E, Castillo AI, Romero J. Cannabinoid CB2 receptors in human brain inflammation. Br J Pharmacol. 2008;153:277-285.

15. Dryburgh LM, Bolan NS, Grof ChPL, Galettis P, Schneider J, et al. Cannabis contaminants: sources, distribution, human toxicity and pharmacologic effects. Br J Clin Pharmacol. 2018;84:2468-2476.

16. Iversen L. Cannabis and the brain. Brain. 2003;126:1252-1270.

17. Filbey FM, Aslan S, Lu H, Peng SL. Residual effects of THC via novel measures of brain perfusion and metabolism in a large group of chronic cannabis users. Neuropsychopharmacology. 2018;43:700-707.

18. Pasman JA, Verweij KJH, Gerring Z, Stringer S, Sanchez-Roige S, Treur JL, et al. GWAS of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal influence of schizophrenia. Nat Neurosci. 2018;21:1161-1170.

19. Nader DA, Sánchez ZM. Effects of regular cannabis use on neurocognition, brain structure, and function: a systematic review of findings in adults. Am J Drug Alcohol Abuse. 2018;44:4-18.

20. Codas M, Haurón G, Achucarro D, Usher F, Pescador-Ruschel MA, Sebriano M, et al. Cannabis en el dolor crónico. Rev Virtual Soc Parag Med Int. 2018;5:12-18.

21. Dryburgh LM, Bolan NS, Grof CPL, Galettis P, Schneider J, Lucas CJ, et al. Cannabis contaminants: sources, distribution, human toxicity and pharmacologic effects. Br J Clin Pharmacol. 2018;84:2468-2476.

22. Bridgeman MB, Abazia DT. Medicinal cannabis: history, pharmacology, and implications for the acute care setting. PT. 2017;42:180-188.

23. Häuser W, Petzke F, Fitzcharles MA. Efficacy, tolerability and safety of cannabis-based medicines for chronic pain management-an overview of systematic reviews. Eur J Pain. 2018;22:455-470.

24. Nugent SM, Morasco BJ, O’Neil ME, Freeman M, Low A, Kondo K, et al. The effects of cannabis among adults with chronic pain and an overview of general harms: a systematic review. Ann Intern Med. 2017;167:319-331.

25. Karila L, Roux P, Rolland B, Benyamina A, Reynaud M, Aubin HJ, et al. Acute and long-term effects of cannabis use: a review. Curr Pharm Des. 2014;20:4112-4118.

26. Perrot S, Trouvin AP. Cannabis for musculoskeletal pain and arthritis: evidence is needed. Joint Bone Spine. 2018;86:1-3.